Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

YBX1 as an oncogenic factor in T-cell acute lymphoblastic leukemia

Open access

Abstract

Y-box-binding protein 1 (YBX1), a member of the RNA-binding protein family, is a critical regulator of cell survival in various solid tumors and acute myeloid leukemia. However, the function of YBX1 in T-cell acute lymphoblastic leukemia (T-ALL) remains elusive. Here, we found that YBX1 was upregulated in patients with T-ALL, T-ALL cell lines, and NOTCH1-induced T-ALL mice. Furthermore, depletion of YBX1 dramatically reduced cell proliferation, induced cell apoptosis, and induced G0/G1 phase arrest in vitro. Moreover, YBX1 depletion significantly decreased the leukemia burden in the human T-ALL xenograft and NOTCH1-induced T-ALL mice model in vivo. Mechanistically, downregulation of YBX1 markedly inhibited the expression of total AKT serine/threonine kinase (AKT), p-AKT, total extracellular signal-regulated kinase (ERK), and p-ERK in T-ALL cells. Taken together, our results uncovered a critical role of YBX1 in the leukemogenesis of T-ALL, which may have great potential as a biomarker and therapeutic target in T-ALL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2022009648

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract Visual Abstract
Graphical abstract Visual AbstractCC BY-NC-ND · PubMed Central
Figure 1. The expression of YBX1 is elevated in T-ALL. (A) The mRNA levels of YBX1 were analyzed in healthy T cells and primary T-ALL cells using microarray data set GSE146901. (B) YBX1 mRNA levels in healthy bone marrow (BM) and T-ALL BMs from microarray data set GSE26713 were analyzed. (C) mRNA expression analysis of YBX1 in T-ALL compared with all cancer types and other hematologic cancers in the Cancer Cell Line Encyclopedia (CCLE) database. (D) The mRNA expression of YBX1 in T cells from healthy donors and patients with T-ALL was determined via qRT-PCR. (E) Relative YBX1 mRNA levels in T cells derived from healthy donors, Jurkat, Molt4, and CCRF-CEM cells. (F) YBX1 mRNA expression was detected in healthy T cells from wild-type mice and leukemia cells from NOTCH1-driven T-ALL mice. (G-I) Western blot analysis of YBX1 expression in healthy T cells and leukemia cells from patients with T-ALL (G), various patient-derived leukemia cell lines (H), and NOTCH1-induced T-ALL mice (I). Glyceraldehyde-3-phosphate dehydrogenase was used as an internal control. (J) Analysis of YBX1 expression in 264 primary T-ALL samples classified into 8 subtypes. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001. N, normal T cells.
Figure 1. The expression of YBX1 is elevated in T-ALL. (A) The mRNA levels of YBX1 were analyzed in healthy T cells and primary T-ALL cells using microarray data set GSE146901. (B) YBX1 mRNA levels in healthy bone marrow (BM) and T-ALL BMs from microarray data set GSE26713 were analyzed. (C) mRNA expression analysis of YBX1 in T-ALL compared with all cancer types and other hematologic cancers in the Cancer Cell Line Encyclopedia (CCLE) database. (D) The mRNA expression of YBX1 in T cells from healthy donors and patients with T-ALL was determined via qRT-PCR. (E) Relative YBX1 mRNA levels in T cells derived from healthy donors, Jurkat, Molt4, and CCRF-CEM cells. (F) YBX1 mRNA expression was detected in healthy T cells from wild-type mice and leukemia cells from NOTCH1-driven T-ALL mice. (G-I) Western blot analysis of YBX1 expression in healthy T cells and leukemia cells from patients with T-ALL (G), various patient-derived leukemia cell lines (H), and NOTCH1-induced T-ALL mice (I). Glyceraldehyde-3-phosphate dehydrogenase was used as an internal control. (J) Analysis of YBX1 expression in 264 primary T-ALL samples classified into 8 subtypes. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001. N, normal T cells.CC BY-NC-ND · PubMed Central
Figure 2. YBX1 inhibition compromises T-ALL cell viability. (A,D) The protein expression of YBX1 was detected via western blot in Jurkat (A) and Molt4 cells (D) with YBX1 knockdown. (B,E) qRT-PCR analysis of YBX1 mRNA expression in Jurkat (B) and Molt4 cells (E). (C,F) Cell viability was determined using MTS assay in Jurkat (C) and Molt4 cells (F). (G) Western blot analysis of YBX1 in Jurkat cells with YBX1 knockout (sgYBX1-1 or sgYBX1-2). (H-I) Cell viability was assessed via MTS after transduction with the indicated lentiviruses in Jurkat cells. ∗∗P<.01; ∗∗∗P<.001.
Figure 2. YBX1 inhibition compromises T-ALL cell viability. (A,D) The protein expression of YBX1 was detected via western blot in Jurkat (A) and Molt4 cells (D) with YBX1 knockdown. (B,E) qRT-PCR analysis of YBX1 mRNA expression in Jurkat (B) and Molt4 cells (E). (C,F) Cell viability was determined using MTS assay in Jurkat (C) and Molt4 cells (F). (G) Western blot analysis of YBX1 in Jurkat cells with YBX1 knockout (sgYBX1-1 or sgYBX1-2). (H-I) Cell viability was assessed via MTS after transduction with the indicated lentiviruses in Jurkat cells. ∗∗P<.01; ∗∗∗P<.001.CC BY-NC-ND · PubMed Central
Figure 3. YBX1 depletion induces apoptosis and cell cycle arrest at the G0/G1 phase in Molt4 and Jurkat cells. (A) Representative images of Wright–Giemsa staining for the morphological analysis of Jurkat and Molt4 cells. (B-C) Cell apoptosis was examined in Jurkat (B) and Molt4 cells (C) with YBX1 knockdown by flow cytometry using annexin V/PI staining. Quantification of cell apoptosis in Jurkat (B) and Molt4 cells (C). (D) Jurkat cells were infected via lentiviruses expressing YBX1 sgRNA (sgYBX1-1 or sgYBX1-2). Quantification of apoptosis in Jurkat cells with YBX1 knockout. (E) Percentages of apoptotic leukemia cells after transduction on day 3. (F) qRT-PCR analysis of mRNA expression of cell apoptosis-related genes. (G-J) Cell cycle was analyzed using flow cytometry with PI staining. (K) Relative mRNA expression of cell cycle-related genes. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001.
Figure 3. YBX1 depletion induces apoptosis and cell cycle arrest at the G0/G1 phase in Molt4 and Jurkat cells. (A) Representative images of Wright–Giemsa staining for the morphological analysis of Jurkat and Molt4 cells. (B-C) Cell apoptosis was examined in Jurkat (B) and Molt4 cells (C) with YBX1 knockdown by flow cytometry using annexin V/PI staining. Quantification of cell apoptosis in Jurkat (B) and Molt4 cells (C). (D) Jurkat cells were infected via lentiviruses expressing YBX1 sgRNA (sgYBX1-1 or sgYBX1-2). Quantification of apoptosis in Jurkat cells with YBX1 knockout. (E) Percentages of apoptotic leukemia cells after transduction on day 3. (F) qRT-PCR analysis of mRNA expression of cell apoptosis-related genes. (G-J) Cell cycle was analyzed using flow cytometry with PI staining. (K) Relative mRNA expression of cell cycle-related genes. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001.CC BY-NC-ND · PubMed Central
Figure 4. YBX1 knockout decreases leukemia burden in the Jurkat xenograft model. (A) Graphical illustration of the Jurkat xenograft model. Jurkat cells were infected with lentiviruses carrying control (sgC) or YBX1 sgRNA (sgYBX1-1 or sgYBX1-2). The protein level of YBX1 was detected via western blot on day 5 after transfection and before transplantation. Approximately 4.5 × 106 cells were injected into NCG mice intravenously, followed by the assessment of leukemia cell dissemination. (B) Protein analysis via western blot. (C) Flow cytometry analysis showing the percentage of hCD45+ cells in the BM on day 42 after transplantation. (D) Representative flow plot showing the frequency of hCD45+ leukemia cells in the BM. (E) Representative hematoxylin and eosin staining images of the BM from each group. (F) Survival curves are displayed using Kaplan-Meier plots (n = 7; long-rank test). ∗∗P < .01; ∗∗∗P < .001. The pattern diagram was drawn using Figdraw.
Figure 4. YBX1 knockout decreases leukemia burden in the Jurkat xenograft model. (A) Graphical illustration of the Jurkat xenograft model. Jurkat cells were infected with lentiviruses carrying control (sgC) or YBX1 sgRNA (sgYBX1-1 or sgYBX1-2). The protein level of YBX1 was detected via western blot on day 5 after transfection and before transplantation. Approximately 4.5 × 106 cells were injected into NCG mice intravenously, followed by the assessment of leukemia cell dissemination. (B) Protein analysis via western blot. (C) Flow cytometry analysis showing the percentage of hCD45+ cells in the BM on day 42 after transplantation. (D) Representative flow plot showing the frequency of hCD45+ leukemia cells in the BM. (E) Representative hematoxylin and eosin staining images of the BM from each group. (F) Survival curves are displayed using Kaplan-Meier plots (n = 7; long-rank test). ∗∗P < .01; ∗∗∗P < .001. The pattern diagram was drawn using Figdraw.CC BY-NC-ND · PubMed Central
Figure 5. YBX1 knockdown impedes leukemogenesis in NOTCH1-induced T-ALL model. (A) Graphical illustration of NOTCH1-induced T-ALL model. C-Kit+ stem and progenitor cells isolated from the BM of 6- or 8-week-old C57/BL6 mice were infected with a retrovirus carrying ICN1 and lentivirus expressing shC or shYBX1. Approximately 2.0 × 105 GFP+ transduced cells were intravenously injected into lethally irradiated mice. The percentage of GFP+ cells in peripheral blood was quantified using flow cytometry on the subsequent days. (B) YBX1 was analyzed before transplantation. (C) Percentages of GFP+ leukemia cells in the peripheral blood were measured via flow cytometry at 4, 5, 6, 7, and 8 weeks after transplantation. (D) Representative spleen images for each group. (E) Spleen weights of the mice in each group were measured. (F-G) GFP+ leukemia cells in the BM (F) and spleen (G) were quantified using flow cytometry on day 53. (H) Survival curves were plotted using the Kaplan-Meier curves (n = 7; long-rank test). ∗P < .05; ∗∗P < .01; ∗∗∗P < .001. The pattern diagram was drawn using Figdraw.
Figure 5. YBX1 knockdown impedes leukemogenesis in NOTCH1-induced T-ALL model. (A) Graphical illustration of NOTCH1-induced T-ALL model. C-Kit+ stem and progenitor cells isolated from the BM of 6- or 8-week-old C57/BL6 mice were infected with a retrovirus carrying ICN1 and lentivirus expressing shC or shYBX1. Approximately 2.0 × 105 GFP+ transduced cells were intravenously injected into lethally irradiated mice. The percentage of GFP+ cells in peripheral blood was quantified using flow cytometry on the subsequent days. (B) YBX1 was analyzed before transplantation. (C) Percentages of GFP+ leukemia cells in the peripheral blood were measured via flow cytometry at 4, 5, 6, 7, and 8 weeks after transplantation. (D) Representative spleen images for each group. (E) Spleen weights of the mice in each group were measured. (F-G) GFP+ leukemia cells in the BM (F) and spleen (G) were quantified using flow cytometry on day 53. (H) Survival curves were plotted using the Kaplan-Meier curves (n = 7; long-rank test). ∗P < .05; ∗∗P < .01; ∗∗∗P < .001. The pattern diagram was drawn using Figdraw.CC BY-NC-ND · PubMed Central
Figure 6. YBX1 regulates the AKT and ERK signaling pathways in T-ALL cells. (A) Volcano plot of differentially expressed genes in RNA-seq at day 3 after knockdown of YBX1 in Jurkat cells. (B) Enrichment of genes in the PI3K/AKT and MAPK pathways using gene set enrichment analysis. (C) Whole cell lysates collected from shC and shYBX1 groups 3 days after infection were analyzed. Western blot was performed to detect the protein expression of p-AKT, total AKT, p-ERK, and total ERK in Jurkat and Molt4 cells. (D) qRT-PCR analysis of mRNA expression of VEGFA and FGFR1. (E) RIP sequencing integrative genomics viewer (IGV) tracks of selected differential gene expression (DEGs) in GSE159153. (F) YBX1 RIP-qPCR analysis showing YBX1 binding to VEGFA and FGFR1 mRNA in HEK293T cells. (G-H) The mRNA half-life of VEGFA (G) and FGFR1 (H) in HEK293T cells. (I-J) Jurkat cells were pretreated with SC79 (1 μg/mL) for 24 hours 2 days after transduction with lentiviruses expressing shRNAs. The percentage of apoptosis was detected via flow cytometry (I), and the mRNA expression of apoptosis-related genes was detected via qRT-PCR (J). (K) Protein expression of p-AKT, total AKT, p-ERK, and total ERK in Jurkat cells was detected via western blot. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001.
Figure 6. YBX1 regulates the AKT and ERK signaling pathways in T-ALL cells. (A) Volcano plot of differentially expressed genes in RNA-seq at day 3 after knockdown of YBX1 in Jurkat cells. (B) Enrichment of genes in the PI3K/AKT and MAPK pathways using gene set enrichment analysis. (C) Whole cell lysates collected from shC and shYBX1 groups 3 days after infection were analyzed. Western blot was performed to detect the protein expression of p-AKT, total AKT, p-ERK, and total ERK in Jurkat and Molt4 cells. (D) qRT-PCR analysis of mRNA expression of VEGFA and FGFR1. (E) RIP sequencing integrative genomics viewer (IGV) tracks of selected differential gene expression (DEGs) in GSE159153. (F) YBX1 RIP-qPCR analysis showing YBX1 binding to VEGFA and FGFR1 mRNA in HEK293T cells. (G-H) The mRNA half-life of VEGFA (G) and FGFR1 (H) in HEK293T cells. (I-J) Jurkat cells were pretreated with SC79 (1 μg/mL) for 24 hours 2 days after transduction with lentiviruses expressing shRNAs. The percentage of apoptosis was detected via flow cytometry (I), and the mRNA expression of apoptosis-related genes was detected via qRT-PCR (J). (K) Protein expression of p-AKT, total AKT, p-ERK, and total ERK in Jurkat cells was detected via western blot. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001.CC BY-NC-ND · PubMed Central
Figure 7. SU056 treatments demonstrate antileukemia efficacy both in vitro and in vivo. (A-B) Cell viability was determined using MTS assay in Jurkat (A) and Molt4 (B) cells treated with SU056 at various concentrations for 48 hours. (C-D) Quantification of cell apoptosis in Jurkat (C) and Molt4 (D) cells treated with SU056 for 48 hours. (E) Percentages of GFP+ leukemia cells in peripheral blood were measured via flow cytometry on day 14. (F-G) GFP+ leukemia cells in the BM (F) and spleen (G) were quantified via flow cytometry on day 16. (H) Survival curves were plotted using the Kaplan-Meier curves (n = 8; long-rank test). ∗P < .05; ∗∗P < .01; ∗∗∗P < .001.
Figure 7. SU056 treatments demonstrate antileukemia efficacy both in vitro and in vivo. (A-B) Cell viability was determined using MTS assay in Jurkat (A) and Molt4 (B) cells treated with SU056 at various concentrations for 48 hours. (C-D) Quantification of cell apoptosis in Jurkat (C) and Molt4 (D) cells treated with SU056 for 48 hours. (E) Percentages of GFP+ leukemia cells in peripheral blood were measured via flow cytometry on day 14. (F-G) GFP+ leukemia cells in the BM (F) and spleen (G) were quantified via flow cytometry on day 16. (H) Survival curves were plotted using the Kaplan-Meier curves (n = 8; long-rank test). ∗P < .05; ∗∗P < .01; ∗∗∗P < .001.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 44 references

Cited by

See all 21

Metadata

Authors
Li, H., Zhang, D., Fu, Q., Wang, S., Wang, Z., Zhang, X., Chen, X., Zhu, X., An, N., Chen, Y., Zhou, L., Lu, D., & Zhao, N.
Affiliations
  • Shenzhen University (CN)
  • Chongqing Medical University (CN)
  • University of Science and Technology of China (CN)
  • Nanjing Medical University (CN)
Corresponding author
Zhao, Na
Venue
Blood Advances
Published
2023-08-24
Volume
7
Issue
17
Pages
4874-4885
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W4381432683
Cited by
21
References
44
Citations by year
2026: 3 · 2025: 10 · 2024: 7 · 2023: 1
FWCI
5.38
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Blood Advances (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
National Natural Science Foundation of China (31970739)
Topics
  • Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Keywords
YB-1, T-cell acute lymphoblastic leukemia, RNA-binding proteins, oncogenic factor, Notch1, Akt signaling, ERK signaling, cell proliferation, apoptosis, G0/G1 cell cycle arrest, leukemogenesis, therapeutic target, biomarkers
MeSH terms
Animals, Humans, T-Lymphocytes, Signal Transduction, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, Mice, Y-Box-Binding Protein 1, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: YBX1 as an oncogenic factor in T-cell acute lymphoblastic leukemia. https://app.cochat.ai/papers/10.1182/bloodadvances.2022009648
The paper
Li, H., Zhang, D., Fu, Q., Wang, S., Wang, Z., Zhang, X., Chen, X., Zhu, X., An, N., Chen, Y., Zhou, L., Lu, D., & Zhao, N. (2023). YBX1 as an oncogenic factor in T-cell acute lymphoblastic leukemia. Blood Advances. https://doi.org/10.1182/bloodadvances.2022009648

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.